Superworth

Spruce Biosciences EPS SPRB

Diluted earnings per share by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
−$41.54
Latest quarter, Q2 FY26
−$6.68
Fiscal year 2025
−$53.37

Spruce Biosciences' earnings per share was −$41.54 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$6.68.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$53.37n/a
FY2024−$96.07n/a
FY2023−$94.50n/a
FY2022−$147.00n/a
FY2021−$135.00n/a
FY2019n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$6.68n/a−$41.54
Q1 FY26−$8.94n/a−$38.36
Q4 FY25−$11.34n/a−$53.37
Q3 FY25−$14.58n/a−$84.62
Q2 FY25−$3.50n/a−$85.79
Q1 FY25−$23.95n/a−$99.02
Q4 FY24−$42.59n/a−$96.07
Q3 FY24−$15.75n/a−$71.48
Q2 FY24−$16.73n/a−$78.23
Q1 FY24−$21.00n/a−$85.50
Q4 FY23−$18.00n/a−$94.50
Q3 FY23−$22.50n/a−$111.75

Against its peers

Companies in Drug Manufacturers - General nearest Spruce Biosciences' size, closest first, today.

CompanyEPS, 12 monthsGrowth
SPRBSpruce Biosciences−$41.54
NATRNatures Sunshine Products$1.01+36% a year
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
ATNMActinium Pharmaceuticals$0.36
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Spruce Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.